Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch & Poster Display session

25P - Analysis of NGS-based blood immune cell RNA signatures for colorectal cancer detection

Date

12 Dec 2019

Session

Lunch & Poster Display session

Presenters

Stephan Morgenthaler

Citation

Annals of Oncology (2019) 30 (suppl_11): xi1-xi11. 10.1093/annonc/mdz447

Authors

S. Morgenthaler1, H. Lindsay2, L. Ciarloni3, P. Angelino4, G. Dorta5, M. Delorenzi6, S. Hosseinian Ehrensberger3

Author affiliations

  • 1 Institute Of Mathematics, Ecole Polytechnique Fédérale de Lausanne, CH-1015 - Lausanne/CH
  • 2 Institute Of Mathematics, Ecole Polytechnique Fédérale de Lausanne, 1015 - Lausanne/CH
  • 3 R&d, Novigenix, 1066 - Epalinges/CH
  • 4 Bioinformatics Core Facility, Swiss Institute of Bioinformatics, 1011 - Lausanne/CH
  • 5 Gastroenterology And Hepatology, CHUV, 1011 - Lausanne/CH
  • 6 Bioinformatics Core Facility, Swiss Institute of Bioinformatics, 1015 - Lausanne/CH
More

Resources

Abstract 25P

Background

Colorectal Cancer (CRC) is the second leading cause of cancer mortality worldwide. Effective and non-invasive biomarkers are needed to improve early diagnosis and disease management. Immune cells play a key role in tumor progression. Circulating immune cell count is a potential cancer biomarker, as indicated by the association of high blood neutrophil-to-lymphocyte ratio with poor prognosis in patients with cancer. The study goal was to determine the correlation between circulating immune cell counts and immune cell-specific RNA signatures and to evaluate the signature potential for CRC detection.

Methods

The transcriptome profiles of peripheral blood mononuclear cells from 561 Asian and Caucasian subjects (189 CRC, 115 advanced adenomas, 39 other cancers, 218 controls without colorectal lesions (CON)) were generated by RNA-seq on the Illumina platform. Neutrophils, lymphocytes and monocytes counts were obtained by standard hematology testing. Specific RNA signatures for neutrophils, monocyte/macrophages, T cells, CD4, CD8, B cells, NK cells were compiled from literature. The mean expression level of all genes in each Immune cell signature was calculated and used for statistical analyses.

Results

The main immune cell type RNA signatures showed correlation with the relative cell counts (r: 0.4-0.6), indicating the validity of the RNA signatures. Myeloid cell (monocyte/macrophage and neutrophil) RNA signatures were the most significantly upregulated in CRC compared to CON (p < 0.01), whereas the T-cell signature was the most significantly downregulated. Interestingly, the NK cell RNA signature was strongly upregulated in the Asian compared to Caucasian patients, which was mirrored by a higher lymphocyte cell count, in line with a previous study.

Conclusion

This study shows that measuring specific immune cell type by RNA signatures correlate with traditional cell counting methods, enabling the extraction of valuable clinical information from blood transcriptomic data. This data suggests that both blood myeloid and T cells RNA signatures are promising biomarkers for CRC detection. Further biomarker development would require the optimization of the RNA signatures to validate and increase their diagnostic power.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Novigenix.

Funding

Novigenix.

Disclosure

S. Morgenthaler: Advisory / Consultancy: Novigenix. L. Ciarloni: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novigenix. G. Dorta: Advisory / Consultancy: Novigenix. S. Hosseinian Ehrensberger: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novigenix. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings